Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy

Karen L. Wood, Chadi Hage, Kenneth S. Knox, Martin B. Kleiman, Aruna Sannuti, Richard B. Day, L. Joseph Wheat, Homer Twigg

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Anti-tumor necrosis factor-α (TNF-α) antibodies are frequently used to treat inflammatory diseases. However, these drugs also have immunosuppressive effects. We report on three patients who developed disseminated histoplasmosis on therapy with TNF-α inhibitors. In vitro assays were used to characterize the role of these agents in host defense against Histoplasma capsulatum. Intracellular proliferation of H. capsulatum was measured in alveolar macrophages and peripheral monocytes of normal volunteers in the presence and absence of the TNF-α antibody, infliximab. Both infliximab and control antibody enhanced fungal growth in monocytes and alveolar macrophages, suggesting this was a nonspecific antibody response. Despite similar intracellular fungal loads in the presence of both antibodies, lymphocyte proliferation in response to blood monocytes and alveolar macrophages infected with H. capsulatum was inhibited by the addition of physiologic doses of infliximab, whereas control antibody had no effect. The production of H. capsulatum-induced interferon-γ and TNF-α was assessed in 5-day cultures containing lymphocytes and alveolar macrophages or monocytes. Interferon-γ secretion was significantly reduced in the presence of infliximab. In summary, patients receiving anti-TNF-α therapy are at risk for developing disseminated histoplasmosis. This may be due to a defect in the TH1 arm of cellular immunity.

Original languageEnglish
Pages (from-to)1279-1282
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume167
Issue number9
DOIs
StatePublished - May 1 2003

Fingerprint

Histoplasmosis
Histoplasma
Alveolar Macrophages
Tumor Necrosis Factor-alpha
Monocytes
Antibodies
Fungal Antibodies
Interferons
Lymphocytes
Therapeutics
Immunosuppressive Agents
Cellular Immunity
Antibody Formation
Healthy Volunteers
Infliximab
Growth
Pharmaceutical Preparations

Keywords

  • Anti-tumor necrosis factor-α antibodies
  • Histoplasmosis
  • Interferon-γ
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. / Wood, Karen L.; Hage, Chadi; Knox, Kenneth S.; Kleiman, Martin B.; Sannuti, Aruna; Day, Richard B.; Wheat, L. Joseph; Twigg, Homer.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 167, No. 9, 01.05.2003, p. 1279-1282.

Research output: Contribution to journalArticle

Wood, Karen L. ; Hage, Chadi ; Knox, Kenneth S. ; Kleiman, Martin B. ; Sannuti, Aruna ; Day, Richard B. ; Wheat, L. Joseph ; Twigg, Homer. / Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. In: American Journal of Respiratory and Critical Care Medicine. 2003 ; Vol. 167, No. 9. pp. 1279-1282.
@article{1a5f5f6f7a4c4baa8c1a382830f0e343,
title = "Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy",
abstract = "Anti-tumor necrosis factor-α (TNF-α) antibodies are frequently used to treat inflammatory diseases. However, these drugs also have immunosuppressive effects. We report on three patients who developed disseminated histoplasmosis on therapy with TNF-α inhibitors. In vitro assays were used to characterize the role of these agents in host defense against Histoplasma capsulatum. Intracellular proliferation of H. capsulatum was measured in alveolar macrophages and peripheral monocytes of normal volunteers in the presence and absence of the TNF-α antibody, infliximab. Both infliximab and control antibody enhanced fungal growth in monocytes and alveolar macrophages, suggesting this was a nonspecific antibody response. Despite similar intracellular fungal loads in the presence of both antibodies, lymphocyte proliferation in response to blood monocytes and alveolar macrophages infected with H. capsulatum was inhibited by the addition of physiologic doses of infliximab, whereas control antibody had no effect. The production of H. capsulatum-induced interferon-γ and TNF-α was assessed in 5-day cultures containing lymphocytes and alveolar macrophages or monocytes. Interferon-γ secretion was significantly reduced in the presence of infliximab. In summary, patients receiving anti-TNF-α therapy are at risk for developing disseminated histoplasmosis. This may be due to a defect in the TH1 arm of cellular immunity.",
keywords = "Anti-tumor necrosis factor-α antibodies, Histoplasmosis, Interferon-γ, Tumor necrosis factor-α",
author = "Wood, {Karen L.} and Chadi Hage and Knox, {Kenneth S.} and Kleiman, {Martin B.} and Aruna Sannuti and Day, {Richard B.} and Wheat, {L. Joseph} and Homer Twigg",
year = "2003",
month = "5",
day = "1",
doi = "10.1164/rccm.200206-563OC",
language = "English",
volume = "167",
pages = "1279--1282",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy

AU - Wood, Karen L.

AU - Hage, Chadi

AU - Knox, Kenneth S.

AU - Kleiman, Martin B.

AU - Sannuti, Aruna

AU - Day, Richard B.

AU - Wheat, L. Joseph

AU - Twigg, Homer

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Anti-tumor necrosis factor-α (TNF-α) antibodies are frequently used to treat inflammatory diseases. However, these drugs also have immunosuppressive effects. We report on three patients who developed disseminated histoplasmosis on therapy with TNF-α inhibitors. In vitro assays were used to characterize the role of these agents in host defense against Histoplasma capsulatum. Intracellular proliferation of H. capsulatum was measured in alveolar macrophages and peripheral monocytes of normal volunteers in the presence and absence of the TNF-α antibody, infliximab. Both infliximab and control antibody enhanced fungal growth in monocytes and alveolar macrophages, suggesting this was a nonspecific antibody response. Despite similar intracellular fungal loads in the presence of both antibodies, lymphocyte proliferation in response to blood monocytes and alveolar macrophages infected with H. capsulatum was inhibited by the addition of physiologic doses of infliximab, whereas control antibody had no effect. The production of H. capsulatum-induced interferon-γ and TNF-α was assessed in 5-day cultures containing lymphocytes and alveolar macrophages or monocytes. Interferon-γ secretion was significantly reduced in the presence of infliximab. In summary, patients receiving anti-TNF-α therapy are at risk for developing disseminated histoplasmosis. This may be due to a defect in the TH1 arm of cellular immunity.

AB - Anti-tumor necrosis factor-α (TNF-α) antibodies are frequently used to treat inflammatory diseases. However, these drugs also have immunosuppressive effects. We report on three patients who developed disseminated histoplasmosis on therapy with TNF-α inhibitors. In vitro assays were used to characterize the role of these agents in host defense against Histoplasma capsulatum. Intracellular proliferation of H. capsulatum was measured in alveolar macrophages and peripheral monocytes of normal volunteers in the presence and absence of the TNF-α antibody, infliximab. Both infliximab and control antibody enhanced fungal growth in monocytes and alveolar macrophages, suggesting this was a nonspecific antibody response. Despite similar intracellular fungal loads in the presence of both antibodies, lymphocyte proliferation in response to blood monocytes and alveolar macrophages infected with H. capsulatum was inhibited by the addition of physiologic doses of infliximab, whereas control antibody had no effect. The production of H. capsulatum-induced interferon-γ and TNF-α was assessed in 5-day cultures containing lymphocytes and alveolar macrophages or monocytes. Interferon-γ secretion was significantly reduced in the presence of infliximab. In summary, patients receiving anti-TNF-α therapy are at risk for developing disseminated histoplasmosis. This may be due to a defect in the TH1 arm of cellular immunity.

KW - Anti-tumor necrosis factor-α antibodies

KW - Histoplasmosis

KW - Interferon-γ

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=0038216657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038216657&partnerID=8YFLogxK

U2 - 10.1164/rccm.200206-563OC

DO - 10.1164/rccm.200206-563OC

M3 - Article

C2 - 12615627

AN - SCOPUS:0038216657

VL - 167

SP - 1279

EP - 1282

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -